In addition, the fda and Health Canada have approved anastrozole, exemestane, and letrozole for use as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer following varying periods of treatment with tamoxifen. This evidence concerns the gene NR4A1 and breast carcinoma.